Hansoh Pharmaceutical Group Co Ltd HNSPF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HNSPF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.57
- Day Range
- $1.88–1.88
- 52-Week Range
- $1.57–1.88
- Bid/Ask
- $1.47 / $3.00
- Market Cap
- $11.14 Bil
- Volume/Avg
- 100 / 101
Key Statistics
- Price/Earnings (Normalized)
- 24.74
- Price/Sales
- 7.92
- Dividend Yield (Trailing)
- 0.82%
- Dividend Yield (Forward)
- 0.82%
- Total Yield
- 0.82%
Company Profile
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 9,123
- Website
- https://www.hspharm.com
Comparables
Valuation
|
Metric
|
HNSPF
|
02552
|
RGC
|
|---|---|---|---|
Price/Earnings (Normalized) | 24.74 | — | — |
Price/Book Value | 3.10 | — | 5.70 |
Price/Sales | 7.92 | 18.32 | — |
Price/Cash Flow | 28.06 | — | — |
Price/Earnings
HNSPF
02552
RGC
Financial Strength
|
Metric
|
HNSPF
|
02552
|
RGC
|
|---|---|---|---|
Quick Ratio | 4.10 | 3.53 | 19.15 |
Current Ratio | 4.21 | 3.80 | 19.15 |
Interest Coverage | 43.91 | −36.00 | — |
Quick Ratio
HNSPF
02552
RGC
Profitability
|
Metric
|
HNSPF
|
02552
|
RGC
|
|---|---|---|---|
Return on Assets (Normalized) | 10.81% | −14.39% | −33.37% |
Return on Equity (Normalized) | 14.31% | — | −35.23% |
Return on Invested Capital (Normalized) | 9.41% | −55.97% | −34.27% |
Return on Assets
HNSPF
02552
RGC
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Mfghjpcl | Gsg | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Bwsbnccmtj | Jgwqqqq | $69.1 Bil | |
HLN
| Haleon PLC ADR | Gxmtddgk | Btrk | $37.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Lhtykjl | Kndv | $15.9 Bil | |
VTRS
| Viatris Inc | Wvzqdczr | Bvlp | $13.8 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Ghgyhlxck | Hrrv | $12.4 Bil | |
CTLT
| Catalent Inc | Dtrnpyqt | Cxfyh | $10.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Mrwzzslt | Hsyb | $4.6 Bil | |
PRGO
| Perrigo Co PLC | Dfcxrwrns | Rwzn | $4.5 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Rzvjpprw | Tbhffd | $3.5 Bil |